Spyre Therapeutics, Inc.
SYRE
$103.63
$1.781.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 47.54% | -10.36% | -459.15% | 69.54% | 17.99% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -316.59% | -43.67% | 163.43% | -3,859.50% | -118.52% |
| Change in Net Operating Assets | -3,792.62% | 110.77% | -138.13% | 165.70% | -1,491.73% |
| Cash from Operations | -21.80% | -28.70% | -20.10% | 20.29% | -13.58% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -626.51% | 122.87% | -1,089.72% | -68.36% | 129,604.92% |
| Cash from Investing | -626.51% | 122.87% | -1,089.72% | -68.36% | 129,604.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,568.27% | -96.03% | 63,623.22% | -32.83% | 235.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -13,476.61% | -147.83% | 98.66% | -- | 100.00% |
| Cash from Financing | 3,430.01% | -96.08% | 6,837.28% | -735.16% | 484.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 465.44% | -44.95% | 224.23% | -150.54% | 181.03% |